Skip to main content

Table 6 Prediction of taxane-anthracycline sensitivity in patients with HER2-negative(HER2-) breast cancer

From: Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

 

pCR prediction(n = 488)

Prediction evaluation*

PPV (SD)

NPV (SD)

Sensitivity (SD)

Specificity (SD)

Unsupervised clustering

    

BRmet50

93(14)

34(3)

58(3)

83(0.6)

PMID18271932Sig33

92(3)

32(5)

53(6)

83(6)

Anthracycline-taxane Centroid

   

BRmet50

89(6)

27(0.6)

40(5)

83(6)

PMID18271932Sig33

77(4)

20(3)

29(1)

67(0.5)